Who owns CONTEXT THERAPEUTICS INC COM?
- Ticker: CNTX
- CUSIP Number: 21077p108
Tip: Access positions for across all investors
Analyze quarterly positions in Context Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Context Therapeutics stock
Who bought or sold CONTEXT THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| MPM Oncology Impact Management | 11M | $16M | -27% | Dec 2025 |
|
| Blue Owl Capital Holdings | 7.4M | $11M | 0% | Dec 2025 |
|
| Deep Track Capital | 7.4M | $11M | 0% | Dec 2025 |
|
| Nextech Invest | 7.4M | $11M | 0% | Dec 2025 |
|
| Avidity Partners Management | 5.5M | $8.1M | -39% | Dec 2025 |
|
| Dr. Jeffrey R. Jay, M.D. | 4.7M | $6.9M | 0% | Dec 2025 |
|
| Franklin Resources | 4.0M | $5.9M | 0% | Dec 2025 |
|
| Vanguard Group | 3.8M | $5.6M | 8% | Dec 2025 |
|
| Marshall Wace | 2.6M | $3.8M | 7154% | Dec 2025 |
|
| Blackstone Group | 2.4M | $2.4M | 0% | Sep 2025 |
|
| Alyeska Investment Group | 1.7M | $2.4M | 0% | Dec 2025 |
|
| Sio Capital Management | 1.3M | $1.3M | 0% | Sep 2025 |
|
| BlackRock | 848k | $1.2M | 0% | Dec 2025 |
|
| Geode Capital Management | 609k | $895k | 0% | Dec 2025 |
|
| Renaissance Technologies | 508k | $747k | 59% | Dec 2025 |
|
| ADAR1 Capital Management | 351k | $516k | 0% | Dec 2025 |
|
| State Street Corporation | 166k | $243k | 9% | Dec 2025 |
|
| Walleye Trading Advisors | 133k | $195k | 0% | Dec 2025 |
|
| HighTower Advisors | 126k | $185k | 0% | Dec 2025 |
|
| Pathstone Holdings | 110k | $162k | 0% | Dec 2025 |
|
| Mill Creek Capital Advisors | 105k | $154k | 0% | Dec 2025 |
|
| Citadel Advisors | 103k | $100k | 100% | Sep 2025 |
|
| XTX Topco | 102k | $149k | 859% | Dec 2025 |
|
| Velan Capital Investment Management | 100k | $147k | 0% | Dec 2025 |
|
| Clear Harbor Asset Management | 93k | $136k | 0% | Dec 2025 |
|
| Northern Trust | 84k | $124k | 27% | Dec 2025 |
|
| Point72 Asset Management | 53k | $78k | 100% | Dec 2025 |
|
| Quadrature Capital | 46k | $68k | 100% | Dec 2025 |
|
| Nantahala Capital Management | 38k | $56k | -98% | Dec 2025 |
|
| Virtu Financial | 29k | $43k | 100% | Dec 2025 |
|
| Advisor Group Holdings | 26k | $38k | 0% | Dec 2025 |
|
| HPM Partners | 20k | $29k | 0% | Dec 2025 |
|
| Caxton | 18k | $27k | 0% | Dec 2025 |
|
| CI Private Wealth | 15k | $22k | 100% | Dec 2025 |
|
| Tower Research Capital | 9.6k | $14k | 100% | Dec 2025 |
|
| Farther Finance Advisors | 1.5k | $2.2k | 100% | Dec 2025 |
|
| UBS Group | 490.00 | $720.006000 | -93% | Dec 2025 |
|
| SBI Securities | 114.00 | $168.001800 | -3% | Dec 2025 |
|
Who sold out of Context Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Affinity Asset Advisors | Sep 2025 | 403k | $390k |
| Qube Research & Technologies | Sep 2025 | 82k | $80k |
| Susquehanna International | Sep 2025 | 22k | $21k |
| Millennium Management | Jun 2025 | 17k | $11k |
| Barclays | Sep 2025 | 167.00 | $162.006700 |